New sponsor requirements add to Indian clinical trial fears
This article was originally published in Scrip
India is said to be putting in place a new requirement in the clinical trials segment, under which sponsors would need to furnish an undertaking of their intent to market the drug under study in India.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.